Search Within

Meghan Caitlin Thompson

Formats
  1. Meeting Abstract (27)
  2. Journal Article (10)
  3. Research Letter (8)
  4. Review (8)
  5. Editorial (2)
  6. Guidelines (1)
Groups
  1. GME, Medicine (56)
  2. Graduate Medical Education (56)
  3. Hematology-Oncology Fellows (56)
  4. Department of Medicine (45)
  5. Hematologic Malignancies, Division of (45)
  6. Adult Leukemia (39)

More Groups

People
  1. Lindsey Roeker (37)
  2. Anthony Mato (30)
  3. Andrew Zelenetz (17)
  4. Mark Geyer (10)
  5. Maria Palomba (9)
  6. Omar Abdel-Wahab (9)

More People

Years
  1. 2025 (8)
  2. 2024 (12)
  3. 2023 (10)
  4. 2022 (9)
  5. 2021 (12)
  6. 2020 (5)
Publications
  1. Blood (25)
  2. American Journal of Hematology (3)
  3. Blood Advances (3)
  4. British Journal of Haematology (3)
  5. Haematologica (3)
  6. Clinical Cancer Research (2)

More Publications

Publishers
  1. American Society of Hematology (29)
  2. John Wiley & Sons (4)
  3. Nature Publishing Group (4)
  4. Ferrata Storti Foundation (3)
  5. Wiley Blackwell (3)
  6. American Association for Cancer Research (2)

More Publishers

Results (56)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies who were previously intolerant to a covalent BTK inhibitor: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Shah, N. N.; Wang, M. L.; Brown, J. R.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)
    Review

    Aronson, J. H.; Skånland, S. S.; Roeker, L. E.; Thompson, M. C.; Mato, A. R.
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
    Research Letter

    Thompson, M. C.; Harrup, R. A.; Coombs, C. C.; Roeker, L. E.; Pu, J. J.; Choi, M. Y.; Barr, P. M.; Allan, J. N.; Šimkovič, M.; Leslie, L.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors
    Journal Article

    Wang, E.; Mi, X.; Thompson, M. C.; Montoya, S.; Notti, R. Q.; Afaghani, J.; Durham, B. H.; Penson, A.; Witkowski, M. T.; Lu, S. X.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Current treatment of chronic lymphocytic leukemia: The diminishing role of chemoimmunotherapy
    Review

    Roeker, L. E.; Thompson, M.; Mato, A. R.
    Drugs (2022)

    Fulltext@MSK | Save
  • Recognizing unmet need in the era of targeted therapy for CLL/SLL: “What's past Is prologue” (Shakespeare)
    Journal Article

    Mato, A. R.; Davids, M. S.; Sharman, J.; Roeker, L. E.; Kay, N.; Kater, A. P.; Rogers, K.; Thompson, M. C.; Rhodes, J.; Goy, A.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save